Restorative Neurostimulation Therapy Compared to Optimal Medical Management: A Randomized Evaluation (RESTORE) for the Treatment of Chronic Mechanical Low Back Pain due to Multifidus Dysfunction.

• Tác giả: Justin V Bundy, Krishnan Chakravarthy, Sherif Costandi, Mehul J Desai, Jonathan Gentile, Christopher Gilligan, Christopher Gilmore, Anthony Giuffrida, Johnathan Goree, Salim Hayek, Robert D Heros, William R Klemme, Meredith Langhorst, Jeff Lehmen, Robert Levy, Smith Manion, Nagy Mekhail, S Craig Meyer, Gregory Moore, Richard Paicius, Kiran V Patel, Vikas V Patel, Jason E Pope, Rebecca Sanders, Frank Schwab, Oszkar Szentirmai, Jordan L Tate, Sandeep Vaid, Sohrab Singh Virk
• Ngôn ngữ: eng
• Ký hiệu phân loại: 248.8085 Guides to Christian life for specific classes of persons
• Thông tin xuất bản: New Zealand : Pain and therapy , 2025
• Bộ sưu tập: NCBI
• ID: 176816

Tóm tắt

 INTRODUCTION: Many interventional strategies are commonly used to treat chronic low back pain (CLBP), though few are specifically intended to target the distinct underlying pathomechanisms causing low back pain. Restorative neurostimulation has been suggested as a specific treatment for mechanical CLBP resulting from multifidus dysfunction. In this randomized controlled trial, we report outcomes from a cohort of patients with CLBP associated with multifidus dysfunction treated with restorative neurostimulation compared to those randomized to a control group receiving optimal medical management (OMM) over 1 year. METHODS: RESTORE is a multicenter, open-label randomized controlled trial. Candidates were assessed for CLBP associated with multifidus dysfunction, with no indication for or history of lumbar spine surgery. Participants were randomized to either restorative neurostimulation with the ReActiv8 system or OMM. The primary endpoint was a comparison of the mean change in the Oswestry Disability Index (ODI) between the treatment and control arms at 1 year, and secondary endpoints included pain (numeric rating scale [NRS]) and health-related quality of life (EuroQol Five-Dimension [EQ-5D-5L]). RESULTS: A total of 203 patients, average age 47 years, and with an average 11-year history of low back pain, were included in the analysis. The primary endpoint was a statistically significant demonstration of a clinically relevant mean improvement in the Oswestry Disability Index (ODI) between restorative neurostimulation and OMM arms: ODI (-19.7 ± 1.4 vs. -2.9 ± 1.4
  p <
  0.001). Additionally, improvements in both the numeric rating scale (NRS) (-3.6 ± 0.2 vs. -0.6 ± 0.2
  p <
  0.001) and EuroQol Five-Dimension (EQ-5D-5L) (0.155 ± 0.012 vs. 0.008 ± 0.012
  p <
  0.001) were statistically and clinically significant in the restorative neurostimulation arm compared to the OMM arm. CONCLUSION: The RESTORE trial demonstrates that restorative neurostimulation is a safe, reversible, clinically effective, and highly durable option for patients suffering with nonoperative CLBP associated with multifidus dysfunction. This demonstration of treatment superiority over OMM through 1 year is a significant milestone in addressing a major health burden and unmet clinical need. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04803214.